SAN FRANCISCO, Jan. 25, 2017 -- FunnelSource, a leading pipeline management and forecasting solution, today announced that it has acquired PipeShot, a company that helps sales teams forecast more accurately using a combination of scientific and gut-driven approaches.
Through this acquisition, FunnelSource expands its forecast offering to support both a bottom-up, data-driven approach as well as a top-down, gut-driven methodology.
John Hanna, CEO of FunnelSource says, “We are extremely excited about the synergies between FunnelSource and PipeShot. As the top-rated pipeline management and forecasting app on the Salesforce AppExchange, FunnelSource was looking to enhance its forecasting suite to meet the evolving needs of high-performing sales organizations. PipeShot is a perfect complement to our existing technology -- it adds flexibility that customers demand, especially those requiring manual forecast and override submissions with history tracking.”
FunnelSource has grown organically with no venture capital funding and has been profitable and debt-free for the past five years. With the all-cash acquisition of PipeShot, FunnelSource is poised to gain market share through continued growth and customer success.
About FunnelSource
FunnelSource is a leader in delivering pipeline management and forecasting solutions to businesses seeking to improve sales effectiveness. Its customers range from venture-backed startups to Fortune 500 companies, and all have turned to FunnelSource to maximize the potential of their pipelines and teams. For more information, please visit:
http://www.funnelsource.com.
About PipeShot
PipeShot is a forecasting application that leverages a combination of scientific and gut-driven data points to help deliver an accurate forecast at every level of the sales organization. For more information, please visit:
http://www.pipeshot.com
Press Contact: (800) 395-7085 [email protected]


Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 



